Method for treating sleep-related breathing disorders
AssigneeCypress Bioscience, Inc.
InventorsSrinivas Rao, Jay Kranzler, Jeffery Anderson
Life of this patent
Estimating the term…
Abstract
Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include mirtazapine in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.
Claims56
A method of treating a sleep related breathing disorder, comprising administering to a patient a therapeutically effective combination of mirtazapine and a second pharmaceutically active ingredient which increases upper airway muscle tone during sleep and stabilizes respiratory drive.
A composition comprising mirtazapine and a second pharmaceutically active ingredient which increases upper airway muscle tone during sleep and stabilizes respiratory drive.
A kit comprising a first dosage form comprising mirtazapine and a second dosage form comprising a second active pharmaceutical ingredient which increases upper airway muscle tone during sleep and stabilizes respiratory drive.
A method of treating a sleep related breathing disorder, comprising administering to a patient a therapeutically effective combination of mirtazapine and a second pharmaceutically active ingredient which stabilizes respiratory drive.
A composition comprising mirtazapine and a second pharmaceutically active ingredient which stabilizes respiratory drive.
A kit comprising a first dosage form containing mirtazapine and a second dosage form comprising a second pharmaceutically active ingredient which stabilizes respiratory drive.
A method of treating a sleep related breathing disorder, comprising administering to a patient a therapeutically effective combination of mirtazapine and a second pharmaceutically active ingredient which treats one of the sequelae of sleep apnea.
A kit comprising a first dosage form comprising mirtazapine and a second dosage form comprising a second pharmaceutically active ingredient which treats one of the sequelae of sleep apnea.
A method of treating a sleep-related breathing disorder, comprising administering to a patient a therapeutically effective amount of a composition comprising mirtazapine and zonisamide.
A method of treating a sleep-related breathing disorder, comprising administering to a patient a therapeutically effective amount of a composition comprising mirtazapine and zonisamide.
A method of treating a sleep-related breathing disorder, comprising administering to a patient a first composition comprising mirtazapine and a second composition comprising zonisamide.
A method of improving patient tolerance to positive airway pressure therapy, comprising administering to the patient a therapeutically effective amount of a composition comprising mirtazapine.
A method of improving patient tolerance to positive airway pressure therapy, comprising administering to the patient a first composition comprising mirtazapine and a second composition comprising zonisamide.
A therapeutic composition for the treatment of a sleep-related breathing disorder, comprising a therapeutically effective amount of mirtazapine.
A method of treating a sleep-related breathing disorder, comprising administering to a patient a therapeutically effective amount of a composition comprising milnacipran.
A method of treating a sleep-related breathing disorder, comprising administering to a patient a first composition comprising milnacipran and a second composition comprising zonisamide.
A method of improving patient response to positive airway pressure therapy, comprising administering to a patient therapeutically effective amount of a composition comprising milnacipran.
A kit for the treatment of a sleep-related breathing disorder, comprising a first dosage form comprising milnacipran and a second dosage form comprising zonisamide.
A pharmaceutical composition for the treatment of a sleep-related breathing disorder, comprising a therapeutically effective amount of a composition comprising milnacipran.
A pharmaceutical composition for the treatment of a sleep-related breathing disorder, comprising a therapeutically effective amount of a combination of zonisamide and milnacipran.
A method of treating a sleep related breathing disorder, comprising administering to a patient a therapeutically effective amount of mirtazapine and amantadine.
A method of treating a sleep related breathing disorder, comprising administering to a patient a therapeutically effective amount of mirtazapine and buproprion.
A method of treating a sleep related breathing disorder, comprising administering to a patient a therapeutically effective amount of mirtazapine and modafinil.
Dependencies are inferred from the claim text.